CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

(2014) C. Costa et al.   CLINICAL CANCER RESEARCH

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

(2013) J. K. Lee et al.   ANNALS OF ONCOLOGY

EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition

(2013) T. Nakagawa et al.   CANCER RESEARCH

Nodal signalling in embryogenesis and tumourigenesis

(2013) Daniela F. Quail et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway

(2013) D F Quail et al.   ONCOGENE

c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met

(2012) L. P. Stabile et al.   CLINICAL CANCER RESEARCH

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

(2012) King Pan Ng et al.   NATURE MEDICINE

ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells

(2011) Xuefeng Liu et al.   AMERICAN JOURNAL OF PATHOLOGY

Expression and functional role of CRIPTO-1 in cutaneous melanoma

(2011) A De Luca et al.   BRITISH JOURNAL OF CANCER

MicroRNA-205 Inhibits Src-Mediated Oncogenic Pathways in Renal Cancer

(2011) S. Majid et al.   CANCER RESEARCH

EMT and Stem Cell-Like Properties Associated with miR-205 and miR-200 Epigenetic Silencing Are Early Manifestations during Carcinogen-Induced Transformation of Human Lung Epithelial Cells

(2011) C. S. Tellez et al.   CANCER RESEARCH

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors

(2011) A. C. Faber et al.   Cancer Discovery

Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers

(2011) H. W. Cheung et al.   Cancer Discovery

Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement

(2011) Alan Serrels et al.   Cell Adhesion & Migration

Role of Src family kinases in acquired resistance to EGFR therapies in cancer

(2010) Julie L. Boerner   CANCER BIOLOGY & THERAPY

Targeting the embryonic gene Cripto-1 in cancer and beyond

(2010) Caterina Bianco et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer

(2010) Masayuki Takeda et al.   Journal of Thoracic Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non–Small-Cell Lung Carcinoma

(2009) Danit Lebanony et al.   JOURNAL OF CLINICAL ONCOLOGY

Src Promotes Survival and Invasion of Lung Cancers with Epidermal Growth Factor Receptor Abnormalities and Is a Potential Candidate for Molecular-Targeted Therapy

(2009) E. L.-H. Leung et al.   MOLECULAR CANCER RESEARCH

CRIPTO3, a presumed pseudogene, is expressed in cancer

(2008) Chao Sun et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells

(2008) Ulrike Burk et al.   EMBO REPORTS

Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer

(2008) X-Y Zhong et al.   HISTOPATHOLOGY

Concurrent Chemoradiotherapy with Cisplatin and Vinorelbine for Stage III Non-small Cell Lung Cancer

(2008) Yoichi Naito et al.   Journal of Thoracic Oncology

Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line

(2008) Jin Kyung Rho et al.   LUNG CANCER

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

(2008) Philip A. Gregory et al.   NATURE CELL BIOLOGY